Dtsch Med Wochenschr 2014; 139(23): 1204-1206
DOI: 10.1055/s-0034-1370011
Endokrinologie & Diabetologie | Commentary
Endokrinologie
© Georg Thieme Verlag KG Stuttgart · New York

Lipoprotein(a) als Arteriosklerose-Risikofaktor

Lipoprotein(a): a risk factor for atherosclerosis
S. Fischer
1   Medizinische Klinik und Poliklinik III des Universitätsklinikums Dresden
,
U. Julius
1   Medizinische Klinik und Poliklinik III des Universitätsklinikums Dresden
,
S. Tselmin
1   Medizinische Klinik und Poliklinik III des Universitätsklinikums Dresden
,
U. Schatz
1   Medizinische Klinik und Poliklinik III des Universitätsklinikums Dresden
,
S. R. Bornstein
1   Medizinische Klinik und Poliklinik III des Universitätsklinikums Dresden
› Author Affiliations
Further Information

Publication History

Publication Date:
27 May 2014 (online)

    Permissions and Reprints

Schlüsselwörter

erhöhter Lipoprotein(a)-Spiegel - Arteriosklerose-Risiko - Diagnostik - Therapie - Lipoprotein-Apherese

Keywords

lipoprotein(a) - atherosclerosis risk - diagnostic - therapy - lipoprotein-apheresis
 

  • Literatur

  • 1 Erqou S, Kaptoge S, Perry PL et al. Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 412-423
    CrossrefPubMedGoogle Scholar
  • 2 Gurdasani D, Sjouke B, Tsimikas S et al. Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol 2012; 32: 3058-3065
    CrossrefGoogle Scholar
  • 3 Jaeger BR, Richter Y, Nagel D et al. Group of Clinical Investigators. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009; 6: 229-239
    CrossrefPubMedGoogle Scholar
  • 4 Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 2014; 11: 470-477
    Google Scholar
  • 5 Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein (a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol 2013; 19: 1146-1156
    Google Scholar
  • 6 Kassner U, Thomas HP, Steinhagen-Thiessen E. Lipoprotein(a): epidemiology and therapeutic approaches. Dtsch Med Wochenschr 2000; 125: 1337-1343
    Article in Thieme ConnectGoogle Scholar
  • 7 Kraft HG, Utermann G. Primäre Dyslipoproteinämien, Lipoprotein(a). 3. Auflage. In: Schwandt P, Parhofer KG, eds, Handbuch der Fettstoffwechselstörungen. Stuttgart, New York: Schattauer; 2006: 216-230
    Google Scholar
  • 8 Leebmann J, Roeseler E, Julius U et al. Pro(a) LiFe Study Group. Lipoprotein apheresis in patients with maximally tolerated lipid lowering therapy, lipoprotein(a)- hyperlipoproteinemia, and progressive cardiovascular disease: Prospective observational multicenter study. Circulation 2013; 128: 2567-2576
    CrossrefPubMedGoogle Scholar
  • 9 Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 2844-2853
    CrossrefGoogle Scholar
  • 10 Parhofer KG. Update Fettstoffwechselstörungen. Internist 2013; 54: 1089-1101
    CrossrefGoogle Scholar
  • 11 Rosada A, Kassner U, Vogt A et al. Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?. Artificial Organs 2014; 38: 135-141
    CrossrefGoogle Scholar
  • 12 Seed M, Hoppichler F, Reavely D et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in familial hypercholesterinemia. N Engl J Med 1990; 322: 1494-1499
    CrossrefGoogle Scholar
  • 13 Tselmin S, Julius U, Müller G et al. Cardiovascular events in patients with increased lipoprotein(a) – retrospective data analysis in an outpatient department of lipid disorders. Atherosclerosis Suppl 2009; 10: 79-84
    CrossrefGoogle Scholar
  • 14 von Dryander M, Fischer S, Passauer J et al. Differences in the atherogenic risk of patients, treated by lipoprotein apheresis according to their lipid pattern. Atherosclerosis Suppl. 2013; 14: 39-44
    CrossrefGoogle Scholar